340 related articles for article (PubMed ID: 30659053)
1. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Josefsson SE; Beiske K; Blaker YN; Førsund MS; Holte H; Østenstad B; Kimby E; Köksal H; Wälchli S; Bai B; Smeland EB; Levy R; Kolstad A; Huse K; Myklebust JH
Cancer Immunol Res; 2019 Mar; 7(3):355-362. PubMed ID: 30659053
[TBL] [Abstract][Full Text] [Related]
2. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
3. TIGIT is a key inhibitory checkpoint receptor in lymphoma.
Godfrey J; Chen X; Sunseri N; Cooper A; Yu J; Varlamova A; Zarubin D; Popov Y; Jacobson C; Postovalova E; Xiang Z; Nomie K; Bagaev A; Venkataraman G; Zha Y; Tumuluru S; Smith SM; Kline JP
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364933
[TBL] [Abstract][Full Text] [Related]
4. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
6. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
8. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
9. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
10. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
11. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
12. TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia.
Zhang X; Zhang H; Chen L; Feng Z; Gao L; Li Q
Cell Immunol; 2019 Oct; 344():103958. PubMed ID: 31376919
[TBL] [Abstract][Full Text] [Related]
13. Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade.
Pearce H; Croft W; Nicol SM; Margielewska-Davies S; Powell R; Cornall R; Davis SJ; Marcon F; Pugh MR; Fennell É; Powell-Brett S; Mahon BS; Brown RM; Middleton G; Roberts K; Moss P
Cancer Immunol Res; 2023 Apr; 11(4):435-449. PubMed ID: 36689623
[TBL] [Abstract][Full Text] [Related]
14. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
15. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
[TBL] [Abstract][Full Text] [Related]
16. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
[TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
18. Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.
Fleury M; Belkina AC; Proctor EA; Zammitti C; Simms RW; Lauffenburger DA; Snyder-Cappione JE; Lafyatis R; Dooms H
Arthritis Rheumatol; 2018 Apr; 70(4):566-577. PubMed ID: 29245183
[TBL] [Abstract][Full Text] [Related]
19. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Johnston RJ; Comps-Agrar L; Hackney J; Yu X; Huseni M; Yang Y; Park S; Javinal V; Chiu H; Irving B; Eaton DL; Grogan JL
Cancer Cell; 2014 Dec; 26(6):923-937. PubMed ID: 25465800
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
